Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher P Fox

Showing results (71-80 of 127) with videos related to

Pageof 13
Sort By:
British Journal of Haematology|April 26, 2019
Male gender is an independent predictor for worse survival and relapse in a large, consecutive cohort of elderly DLBCL patients treated with R-CHOPToby A Eyre, Nicolas Martinez-Calle, Catherine Hildyard, et al.
British Journal of Haematology|July 17, 2018
Guideline for the treatment of chronic lymphocytic leukaemia: A British Society for Haematology GuidelineAnna H Schuh, Nilima Parry-Jones, Niamh Appleby, et al.
British Journal of Haematology|June 22, 2019
Stand-alone intrathecal central nervous system (CNS) prophylaxis provide unclear benefit in reducing CNS relapse risk in elderly DLBCL patients treated with R-CHOP and is associated increased infection-related toxicityToby A Eyre, Amy A Kirkwood, Julia Wolf, et al.
British Journal of Haematology|March 23, 2023
Venetoclax ramp-up strategies for chronic lymphocytic leukaemia in the United Kingdom: a real world multicentre retrospective studyRocio Figueroa-Mora, Alexandros Rampotas, Daniel Halperin, et al.
Blood Advances|April 23, 2021
Infection-related morbidity and mortality among older patients with DLBCL treated with full- or attenuated-dose R-CHOPToby A Eyre, William Wilson, Amy A Kirkwood, et al.
The British Journal of Dermatology|November 6, 2023
Discontinuation of anti-tumour necrosis factor alpha treatment owing to blood test abnormalities, and cost-effectiveness of alternate blood monitoring strategiesAbhishek Abhishek, Matthew D Stevenson, Georgina Nakafero, et al.
British Journal of Haematology|January 31, 2020
Induction therapy with the MATRix regimen in patients with newly diagnosed primary diffuse large B-cell lymphoma of the central nervous system - an international study of feasibility and efficacy in routine clinical practiceElisabeth Schorb, Christopher P Fox, Benjamin Kasenda, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 12, 2019
Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY StudyPeter Hillmen, Andy C Rawstron, Kristian Brock, et al.
Hemasphere|June 5, 2024
Primary central nervous system lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAndreas J M Ferreri, Gerald Illerhaus, Jeanette K Doorduijn, et al.
Advances in Therapy|May 26, 2021
Systemic ALCL Treated in Routine Clinical Practice: Outcomes Following First-Line Chemotherapy from a Multicentre CohortNicolas Martinez-Calle, Amy A Kirkwood, Maxine Lamb, et al.
Pageof 13

Showing results (71-80 of 127) with videos related to

Sort By:
Pageof 13
British Journal of Haematology|April 26, 2019
Male gender is an independent predictor for worse survival and relapse in a large, consecutive cohort of elderly DLBCL patients treated with R-CHOPToby A Eyre, Nicolas Martinez-Calle, Catherine Hildyard, et al.
British Journal of Haematology|July 17, 2018
Guideline for the treatment of chronic lymphocytic leukaemia: A British Society for Haematology GuidelineAnna H Schuh, Nilima Parry-Jones, Niamh Appleby, et al.
British Journal of Haematology|June 22, 2019
Stand-alone intrathecal central nervous system (CNS) prophylaxis provide unclear benefit in reducing CNS relapse risk in elderly DLBCL patients treated with R-CHOP and is associated increased infection-related toxicityToby A Eyre, Amy A Kirkwood, Julia Wolf, et al.
British Journal of Haematology|March 23, 2023
Venetoclax ramp-up strategies for chronic lymphocytic leukaemia in the United Kingdom: a real world multicentre retrospective studyRocio Figueroa-Mora, Alexandros Rampotas, Daniel Halperin, et al.
Blood Advances|April 23, 2021
Infection-related morbidity and mortality among older patients with DLBCL treated with full- or attenuated-dose R-CHOPToby A Eyre, William Wilson, Amy A Kirkwood, et al.
The British Journal of Dermatology|November 6, 2023
Discontinuation of anti-tumour necrosis factor alpha treatment owing to blood test abnormalities, and cost-effectiveness of alternate blood monitoring strategiesAbhishek Abhishek, Matthew D Stevenson, Georgina Nakafero, et al.
British Journal of Haematology|January 31, 2020
Induction therapy with the MATRix regimen in patients with newly diagnosed primary diffuse large B-cell lymphoma of the central nervous system - an international study of feasibility and efficacy in routine clinical practiceElisabeth Schorb, Christopher P Fox, Benjamin Kasenda, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 12, 2019
Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY StudyPeter Hillmen, Andy C Rawstron, Kristian Brock, et al.
Hemasphere|June 5, 2024
Primary central nervous system lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAndreas J M Ferreri, Gerald Illerhaus, Jeanette K Doorduijn, et al.
Advances in Therapy|May 26, 2021
Systemic ALCL Treated in Routine Clinical Practice: Outcomes Following First-Line Chemotherapy from a Multicentre CohortNicolas Martinez-Calle, Amy A Kirkwood, Maxine Lamb, et al.
Pageof 13